Early detection of osteoporosis from routine wrist radiographs
Supporting Healthy Ageing For All
Bone health diagnosis from
routine digital radiography
IBEX is on a mission to support healthy ageing for all by providing routine access to osteoporosis diagnosis.
IBEX BH is a software solution that provides areal bone mineral density outputs from a standard digital radiograph. This software can be used to opportunistically screen patients and enables earlier and more widespread diagnosis of osteoporosis.
Osteoporosis – the silent disease
About 1 in 3 women and 1 in 5 men over 50 will break a bone in their lifetime due to osteoporosis¹ and the hospitalisation burden of osteoporotic fractures is greater than that of heart attacks, stroke, and breast cancer².
Often referred to as ‘the silent disease’ as patients often don’t experience any symptoms until they experience their first fracture, osteoporosis remains undiagnosed in around 80% of cases due to lack of screening and long waiting times for DXA scans³.
DXA outputs from
IBEX BH identifies patients at heightened risk of fracture by returning the same outputs as DXA, providing clear guidance to support downstream care.
IBEX BH delivers a measure of aBMD, T score, and probability of osteoporosis at the femoral neck.
The software is fully automated, with no change needed to exam protocol or hardware.
The Benefits of IBEX BH
IBEX is an accurate case-finding tool aligned to standard clinical workflow, meaning that patients can be opportunistically identified and treated for osteoporosis.
Healthcare economics modelling shows that IBEX BH will reduce healthcare provider costs and improve patient outcomes.
Findings from a 261-patient trial in partnership with the University of Exeter showed that IBEX BH is able to accurately measure areal bone mineral density and T-score at the wrist. This provides a clinically useful screening test for osteoporosis and is a more accurate and accessible alternative to current screening.
Outcomes at the wrist were also found to be as predictive as a vertebral DXA scan when predicting osteoporosis at the hip.
IBEX BH is undergoing CE marking for clinical use on forearm imaging in 2023 and a clinical study to extend compatibility to other body parts is also starting in 2023. Results will be published on the website following peer review.
We’d love to hear from you
IBEX is seeking partnerships with leading OEMs to bring IBEX BH to market. If you’re interested in the rare opportunity to add significant value and expand market share, please contact us to discuss an evaluation on your systems.
IBEX is currently establishing pilots and reference sites. If you’d like to be considered for piloting this unique technology at your clinic, please get in touch.
1 – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335887/#:~:text=According%20to%20recent%20statistics%20from,sign%20of%20another%20impending%20one.
2 – https://pubmed.ncbi.nlm.nih.gov/25481833/
3 – https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures